Evidence map›Paper›PMID 23684623›Full record

ReviewCell metabolism2013

Pharmacology, physiology, and mechanisms of incretin hormone action.

Jonathan E Campbell, Daniel J Drucker

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Cell metabolism, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02598791 (GIP/GLP-1 Co-Activity in Subjects With Obesity), which is not on this map. Cited by 702 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
702citing papers in PubMed, 12 pooled it
70.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02598791 nacompletedstarted 2015, after this paper: background citation

GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake

Ran2015Enrolled18Registered outcomes12Posted comparisons0ConditionsAdiposity, Obesity, Type 2 DiabetesArmsIIGI+GIP, IIGI+GIP+GLP-1, IIGI+GLP-1, IIGI+NaCl (placebo), OGTT
PMID 24174327PMID 9449682PMID 25144635other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

702 citing papers in PubMed, 12 syntheses or guidelines pooled it, 1,426 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Regional organization of nutrient absorption across the small intestine.Nature reviews. Gastroenterology & hepatology · 2026
    Review

642 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jonathan E CampbellDepartment of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada.
Daniel J DruckerDepartment of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada. Electronic address: d.drucker@utoronto.ca.
Mount Sinai Hospital · CA

Funding

Canadian Institutes of Health Research MOP 82700
6 · The paper itself

Abstract

Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose concentrations, lipid metabolism, gut motility, appetite and body weight, and immune function, providing a scientific basis for utilizing incretin-based therapies in the treatment of type 2 diabetes. Activation of GLP-1 and GIP receptors also leads to nonglycemic effects in multiple tissues, through direct actions on tissues expressing incretin receptors and indirect mechanisms mediated through neuronal and endocrine pathways. Here we contrast the pharmacology and physiology of incretin hormones and review recent advances in mechanisms coupling incretin receptor signaling to pleiotropic metabolic actions in preclinical studies. We discuss whether mechanisms identified in preclinical studies have potential translational relevance for the treatment of human disease and highlight controversies and uncertainties in incretin biology that require resolution in future studies.

Indexed as

AnimalsGastric Inhibitory PolypeptideGlucagon-Like Peptide 1HumansIncretinsIslets of LangerhansMiceReceptors, Gastrointestinal HormoneSignal TransductionGastric Inhibitory Polypeptidegastric inhibitory polypeptide receptorGlucagon-Like Peptide 1IncretinsReceptors, Gastrointestinal Hormone

Identifiers

PMID23684623
OpenAlexW1967442749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.